Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1136/gut.2009.200642. Epub 2010 Mar 26.
Affiliations
- PMID: 20348368
- DOI: 10.1136/gut.2009.200642
Randomized Controlled Trial
Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis
Nicholas J West et al. Gut. 2010 Jul.
Abstract
Objective: The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) has anticolorectal cancer activity in vitro and in preclinical models. The present study tested whether a novel, enteric-coated formulation of EPA, as the free fatty acid (EPA-FFA), has chemopreventative efficacy in patients with familial adenomatous polyposis (FAP), in a randomised, double-blind, placebo-controlled trial.
Methods: Patients undergoing endoscopic surveillance of their retained rectum postcolectomy were randomised to EPA-FFA (SLA Pharma) 2 g daily or placebo for 6 months. The number and size of polyps in an area of mucosa defined by a tattoo were determined before and after intervention. Global rectal polyp burden was scored (-1, 0, +1) by examination of video endoscopy records. Mucosal fatty acid content was measured by gas chromatography-mass spectrometry.
Results: 55 patients with FAP were evaluated by an intention-to-treat analysis (EPA-FFA 28, placebo 27). Treatment with EPA-FFA for 6 months was associated with a mean 22.4% (95% CI 5.1% to 39.6%) reduction in polyp number (p=0.012) and a 29.8% (3.6% to 56.1%) decrease in the sum of polyp diameters (p=0.027). Global polyp burden worsened over 6 months in the placebo group (-0.34) unlike the EPA-FFA group (+0.09, difference 0.42 (0.10-0.75), p=0.011). EPA-FFA treatment led to a mean 2.6-fold increase in mucosal EPA levels (p=0.018 compared with placebo). EPA-FFA was well tolerated with an incidence of adverse events similar to placebo.
Conclusions: EPA-FFA has chemopreventative efficacy in FAP, to a degree similar to that previously observed with selective cyclo-oxygenase-2 inhibitors. EPA holds promise as a colorectal cancer chemoprevention agent with a favourable safety profile.
Trial registration: ClinicalTrials.gov NCT00510692.
Comment in
- Eicosapentaenoic acid and chemoprevention of FAP.
Lynch PM. Lynch PM. Gut. 2010 Jul;59(7):871-3. doi: 10.1136/gut.2009.204677. Gut. 2010. PMID: 20581233 No abstract available.
Similar articles
- Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.
Cockbain AJ, Volpato M, Race AD, Munarini A, Fazio C, Belluzzi A, Loadman PM, Toogood GJ, Hull MA. Cockbain AJ, et al. Gut. 2014 Nov;63(11):1760-8. doi: 10.1136/gutjnl-2013-306445. Epub 2014 Jan 27. Gut. 2014. PMID: 24470281 Clinical Trial. - A novel bioactive derivative of eicosapentaenoic acid (EPA) suppresses intestinal tumor development in ApcΔ14/+ mice.
Nakanishi M, Hanley MP, Zha R, Igarashi Y, Hull MA, Mathias G, Sciavolino F, Grady JJ, Rosenberg DW. Nakanishi M, et al. Carcinogenesis. 2018 Mar 8;39(3):429-438. doi: 10.1093/carcin/bgx136. Carcinogenesis. 2018. PMID: 29206907 - Omega-3 polyunsaturated fatty acids.
Hull MA. Hull MA. Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):547-54. doi: 10.1016/j.bpg.2011.08.001. Best Pract Res Clin Gastroenterol. 2011. PMID: 22122770 Review. - Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P. Cooper K, et al. Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320. Health Technol Assess. 2010. PMID: 20594533 Review.
Cited by
- Endoscopic scoring indices for assessing disease severity in familial adenomatous polyposis: Systematic review.
Silverman AL, Bouchiba H, Aelvoet A, MacDonald J, Dekker E, Zayadi A, Le J, Feagan B, Jairath V, Ma C, Samadder J. Silverman AL, et al. Endosc Int Open. 2024 Jun 18;12(6):E799-E809. doi: 10.1055/a-2330-8037. eCollection 2024 Jun. Endosc Int Open. 2024. PMID: 38904059 Free PMC article. Review. - Fatty acid desaturase insertion-deletion polymorphism rs66698963 predicts colorectal polyp prevention by the n-3 fatty acid eicosapentaenoic acid: a secondary analysis of the seAFOod polyp prevention trial.
Sun G, Li YN, Davies JR, Block RC, Kothapalli KS, Brenna JT, Hull MA. Sun G, et al. Am J Clin Nutr. 2024 Aug;120(2):360-368. doi: 10.1016/j.ajcnut.2024.06.004. Epub 2024 Jun 13. Am J Clin Nutr. 2024. PMID: 38879016 Free PMC article. Clinical Trial. - Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision.
Zaffaroni G, Mannucci A, Koskenvuo L, de Lacy B, Maffioli A, Bisseling T, Half E, Cavestro GM, Valle L, Ryan N, Aretz S, Brown K, Buttitta F, Carneiro F, Claber O, Blanco-Colino R, Collard M, Crosbie E, Cunha M, Doulias T, Fleming C, Heinrich H, Hüneburg R, Metras J, Nagtegaal I, Negoi I, Nielsen M, Pellino G, Ricciardiello L, Sagir A, Sánchez-Guillén L, Seppälä TT, Siersema P, Striebeck B, Sampson JR, Latchford A, Parc Y, Burn J, Möslein G. Zaffaroni G, et al. Br J Surg. 2024 May 3;111(5):znae070. doi: 10.1093/bjs/znae070. Br J Surg. 2024. PMID: 38722804 Free PMC article. - Chemoprevention in Inherited Colorectal Cancer Syndromes.
Gilad O, Muller C, Kupfer SS. Gilad O, et al. Clin Colon Rectal Surg. 2023 Jul 19;37(3):172-179. doi: 10.1055/s-0043-1770384. eCollection 2024 May. Clin Colon Rectal Surg. 2023. PMID: 38606042 Free PMC article. Review. - The Salmon Oil OmeGo Reduces Viability of Colorectal Cancer Cells and Potentiates the Anti-Cancer Effect of 5-FU.
Pettersen CHH, Samdal H, Sætrom P, Wibe A, Hermansen E, Schønberg SA. Pettersen CHH, et al. Mar Drugs. 2023 Dec 12;21(12):636. doi: 10.3390/md21120636. Mar Drugs. 2023. PMID: 38132957 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous